CD4 and Cryptococcal meningitis: Based upon existing estimates that cryptococcal meningitis prevalence is 6% in patients with CD4 < 100 at the time of antiretroviral initiation, [9] we believe the 76 patients included in this study is representative of the cases with CD4 < 100 (1460 patients) within the MAM cohort during this study period.